0.00Open0.00Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover448.44%IV-177.78%PremiumSep 20, 2024Expiry Date12.80Intrinsic Value100Multiplier5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9552Delta0.0260Gamma0.56Leverage Ratio-0.0286Theta-0.0017Rho-0.53Eff Leverage0.0008Vega
Kyverna Therapeutics Stock Discussion
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet